SELECT: Semaglutide Reduces CV Events and Diabetes Risk
Two new analyses of the SELECT trial show that the GLP-1 receptor agonist improves cardiovascular health and reduces or normalizes glycemic levels irrespective of baseline A1c.
Medscape Medical News
source https://www.medscape.com/viewarticle/select-semaglutide-reduces-cv-events-and-diabetes-risk-2024a1000bma?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/select-semaglutide-reduces-cv-events-and-diabetes-risk-2024a1000bma?src=rss
Comments
Post a Comment